Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN7 | P35236 | 1/20 | 0.55 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9939319 | 0.90 | PTPN7 (0.56) | PTPN7P2RY14MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL9939296 | 0.90 | P2RY14 (0.59) | P2RY14MEN1KMT2ASMN1; SMN2ALOX5 | |
| SCHEMBL9939405 | 0.85 | PTPN7 (0.52) | PTPN7P2RY14MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL28152490 | 0.84 | ALOX5 (0.67) | MEN1KMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL1777985 | 0.83 | ALOX5 (0.60) | P2RY14MEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL1779167 | 0.83 | ALOX5 (0.59) | P2RY14MEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL9939093 | 0.81 | PTPN7 (0.50) | PTPN7P2RY14MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL9268448 | 0.81 | NPC1 (0.71) | PTPN7MEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL9343582 | 0.80 | SMN1; SMN2 (0.65) | MEN1KMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL978502 | 0.79 | RAB9A (0.71) | MEN1KMT2ASMN1; SMN2MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160108011-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC | 2016-04-21 | — | — | US | disclosed |
| US-9249132-B2 | Substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| EP-2651871-A1 | NOVEL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 Pharmaceuticals, Inc. (US) | 2013-10-23 | — | — | EP | disclosed |
| US-20130261122-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 Pharmaceuticls, Inc. (US) | 2013-10-03 | — | — | US | disclosed |
| CN-103328430-A | Novel substituted bicyclic aromatic compounds as s-nitrosoglutathione reductase inhibitors | N30 PHARMACEUTICALS LLC | 2013-09-25 | — | — | CN | disclosed |
| WO-2012170371-A1 | COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 PHARMACEUTICALS, LLC (US) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012083171-A1 | NOVEL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 PHARMACEUTICALS, LLC (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108011-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | GSR, CBR1, POR | PTPN7 2754/4885P2RY14 4423/4885MEN1 4669/4885 |
| US-20130261122-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | GSR, CBR1, POR | PTPN7 2754/4885P2RY14 4423/4885MEN1 4669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.